Abstract 3287: Lack of Evidence of a Clopidogrel-Statin Interaction in the CHARISMA Trial

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Circulation

• Publication date

  2006-10-31

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Does it take two to tango?

  2024cites this paper
• Development and validation of a sensitive LC-MS/MS method for simultaneous analysis of clopidogrel and simvastatin and their main metabolites in beagles: Application to pharmacokinetic drug interactions.

  2023cites this paper
• Isparta ve çevresinde klopidogrel direncinin araştırılması

  2020cites this paper
• Puncture site bleeding complications in patients with Clopidogrel hyper-response

  2020cites this paper
• Prescription switching: Rationales and risks

  2020cites this paper
• Clopidogrel drug interactions: a review of the evidence and clinical implications

  2020cites this paper
• Prevention of cardiovascular outcomes in diabetic patients with atrial fibrillation: direct oral anticoagulants or warfarin?

  2019cites this paper
• Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty.

  2019cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis

  2019cites this paper
• Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance

  2018cites this paper
• Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease: Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE)

  2018cites this paper
• Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians

  2018cites this paper
• Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors.

  2017cites this paper
• Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke

  2016cites this paper
• Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.

  2016cites this paper
• Clopidogrel-Statin Interaction: a Missing Links

  2016cites this paper
• Clinical relevance of clopidogrel-proton pump inhibitors interaction.

  2015cites this paper
• Variantes genéticas y su relación con la progresión y el pronóstico de la cardiopatía isquémica

  2015cites this paper
• Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin.

  2015cites this paper
• Aortic Atherosclerosis as an Embolic Source

  2015cites this paper
• Revisiting the Clopidogrel-Proton Pump Inhibitor Interaction: From Bench to Bedside.

  2015cites this paper
• Antiplatelet resistance in outpatients with monitored adherence

  2014cites this paper
• Newer Antiplatelet Agents for Interventional Indications

  2014cites this paper
• Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.

  2014cites this paper
• Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors

  2014cites this paper
• Other Drug Interactions with Clopidogrel

  2014cites this paper
• Society for Vascular Nursing clinical practice guideline (CPG) for carotid artery stenting.

  2013cites this paper
• Chapter 4 – Pharmacogenetics

  2013cites this paper
• Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations

  2013cites this paper
• ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.

  2013cites this paper
• Clopidogrel "resistance": pre- vs post-receptor determinants.

  2013cites this paper
• Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.

  2013cites this paper
• CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition

  2013cites this paper
• Drug interactions with statins

  2013cites this paper
• Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs

  2013cites this paper
• Clopidogrel Interactions: Consider while prescribing

  2013cites this paper
• Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives

  2012cites this paper
• The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment

  2012cites this paper
• InforMatrix: ADP antagonists in acute coronary syndromes

  2012cites this paper
• Thrombozytenfunktion – neue Medikamente, neue Assays

  2012cites this paper
• Current therapy of non-ST-elevation acute coronary syndromes.

  2012cites this paper
• The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina.

  2012cites this paper
• Blockbuster interactions: are they bad for the patient?

  2012cites this paper
• Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome

  2012cites this paper
• Drug-drug interactions in cardiovascular catheterizations and interventions.

  2012cites this paper
• Thienopyridines and other ADP-receptor antagonists.

  2012cites this paper
• Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

  2012cites this paper
• Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate

  2012cites this paper
• Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.

  2012cites this paper
• Simvastatin interactions with other drugs

  2012cites this paper
• Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.

  2012cites this paper
• A comprehensive comparative review of adenosine diphosphate receptor antagonists

  2012cites this paper
• Análisis de las interacciones medicamentosas asociadas a la farmacoterapia domiciliaria en pacientes ancianos hospitalizados

  2011cites this paper
• Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.

  2011cites this paper
• Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period

  2011cites this paper
• High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment.

  2011cites this paper
• Review: Antiplatelet Therapy in Acute Coronary Syndromes

  2011cites this paper
• ESTIMATION OF CLINICAL PHARMACOKINETIC INTERACTION BETWEEN ATORVASTATIN AND CLOPIDOGREL IN ATHEROSCLEROTIC HEART DISEASE PATIENTS

  2011cites this paper
• Oral antiplatelet therapy

  2011cites this paper
• Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.

  2011cites this paper
• Clopidogrel-drug interactions.

  2011cites this paper
• Clopidogrel and Salicylates

  2011cites this paper
• Review article: proton pump inhibitors with clopidogrel – evidence for and against a clinically‐important interaction

  2011cites this paper
• The safety of clopidogrel

  2011cites this paper
• Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.

  2011cites this paper
• Platelet function variability and non-genetic causes

  2011cites this paper
• CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango?

  2011cites this paper
• Inhibidores de la bomba de protones y clopidogrel en el paciente cardiovascular: ¿riesgo cardiovascular versus riesgo gastrointestinal?

  2010cites this paper
• Epidemiology of Cytochrome P450-mediated Drug-Drug Interactions

  2010cites this paper
• Drugs that affect blood coagulation, fibrinolysis, and hemostasis

  2010cites this paper
• 44 - Drugs that affect lipid metabolism

  2010cites this paper
• Factors associated with clopidogrel nonresponsiveness.

  2010cites this paper
• Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions.

  2010cites this paper
• Scarsa risposta al clopidogrel: attuali opzioni di trattamento e scenari futuri

  2010cites this paper
• Omeprazole and clopidogrel: Should clinicians be worried?

  2010cites this paper
• [Current options to manage clopidogrel poor responsiveness].

  2010cites this paper
• Clopidogrel Before Elective Percutaneous Coronary Intervention

  2010cites this paper
• Statins and prophylaxis of venous thrombosis – a further link between arterial and venous thrombosis

  2010cites this paper
• Safety of Proton Pump Inhibitors: Current Evidence for Osteoporosis and Interaction with Antiplatelet Agents

  2010cites this paper
• Omeprazole and Clopidogrel: Should Clinicians Be Worried? Cleveland Clinic Journal of Medicine Volume 77 @bullet Number 2

  2010cites this paper
• Variabilité de réponse au clopidogrel : bases biologiques, mécanismes, conséquences cliniques et alternatives thérapeutiques

  2010cites this paper
• Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?

  2010cites this paper
• Advance of pharmacological studies on clopidogrel, a prodrug with high-risk pharmacokinetics

  2010cites this paper
• Clinical importance of aspirin and clopidogrel resistance.

  2010cites this paper
• Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.

  2010cites this paper
• Poor response to clopidogrel: current and future options for its management

  2010cites this paper
• Pharmacologic Interactions in the CICU

  2010cites this paper
• Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction

  2010cites this paper
• Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro

  2010cites this paper
• Clopidogrel pathway.

  2010cites this paper
• Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation).

  2010cites this paper
• Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras

  2010cites this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cites this paper
• Should routine platelet testing be done on all patients undergoing percutaneous coronary intervention? Routine Platelet Testing Should Not Be Performed on All Patients Undergoing Percutaneous Coronary Intervention

  2010cites this paper
• Conflicting Evidence: What's a Clinician to Do?

  2010cites this paper
• Proton pump inhibitors and clopidogrel.

  2010cites this paper
• Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention.

  2010cites this paper
• The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.

  2010cites this paper
• Leczenie dużymi dawkami statyn: korzyści i bezpieczeństwo intensywnej terapii

  2009cites this paper